{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:03:56Z","timestamp":1779617036971,"version":"3.53.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["24236"],"award-info":[{"award-number":["24236"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-INBS-0009"],"award-info":[{"award-number":["ANR-10-INBS-0009"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-INBS-04"],"award-info":[{"award-number":["ANR-10-INBS-04"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031376","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie","doi-asserted-by":"publisher","award":["SFR 2018"],"award-info":[{"award-number":["SFR 2018"]}],"id":[{"id":"10.13039\/100031376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["22425"],"award-info":[{"award-number":["22425"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ard.2025.08.031","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:57:13Z","timestamp":1759813033000},"page":"2049-2064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-8088","authenticated-orcid":false,"given":"L\u00e9a","family":"Debrut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4834-5804","authenticated-orcid":false,"given":"Margherita","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rovito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Keime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Lannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Geny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Laverny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ard.2025.08.031_bib0001","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.42561","article-title":"Refining incidence and characteristics of inflammatory myopathies: a quadruple-source capture-recapture survey using the 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria","volume":"75","author":"Debrut","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"ENMC 239th Workshop Study Group. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.ard.2025.08.031_bib0003","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis","volume":"42","author":"Pinal-Fernandez","year":"2015","journal-title":"J Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.ard.2025.08.031_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000784","article-title":"Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]","volume":"4","author":"Meyer","year":"2018","journal-title":"RMD Open"},{"issue":"21","key":"10.1016\/j.ard.2025.08.031_bib0005","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ard.2025.08.031_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.ard.2025.08.031_bib0007","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","article-title":"T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells","volume":"183","author":"Fasth","year":"2009","journal-title":"J Immunol"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.08.031_bib0008","article-title":"Muscle fibres play a critical role in therapeutic response of myositis to glucocorticoids through polarisation of the inflammatory infiltrate by a paracrine mechanism [abstract]","volume":"74","author":"Giannini","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0009","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ard.2025.08.031_bib0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0012","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-017-1383-0","article-title":"RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis","volume":"19","author":"Su\u00e1rez-Calvet","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ard.2025.08.031_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35056572","article-title":"Antigen processing by the proteasome","volume":"2","author":"Kloetzel","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0014","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.031_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1529582","article-title":"Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis","volume":"16","author":"Bolko","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ard.2025.08.031_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065362","article-title":"Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15","volume":"8","author":"Franzi","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ard.2025.08.031_bib0018","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.08.031_bib0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.183.4.1807","article-title":"Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma","volume":"183","author":"Hisamatsu","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2025.08.031_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-\u03b3-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ard.2025.08.031_bib0022","doi-asserted-by":"crossref","first-page":"L248","DOI":"10.1152\/ajplung.2001.280.2.L248","article-title":"IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells","volume":"280","author":"Jamaluddin","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"10.1016\/j.ard.2025.08.031_bib0023","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI29832","article-title":"Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection","volume":"116","author":"Shin","year":"2006","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ard.2025.08.031_bib0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"issue":"307","key":"10.1016\/j.ard.2025.08.031_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4227","article-title":"Human IFNAR2 deficiency: lessons for antiviral immunity","volume":"7","author":"Duncan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.ard.2025.08.031_bib0026","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/jnen\/nlae098","article-title":"Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups: a histopathological cohort study","volume":"83","author":"Lessard","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Database issue","key":"10.1016\/j.ard.2025.08.031_bib0027","first-page":"D1040","article-title":"Interferome v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"26","key":"10.1016\/j.ard.2025.08.031_bib0028","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.ard.2025.08.031_bib0029","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1093\/brain\/awaf153","article-title":"Interferon-\u03b3 causes myogenic cell dysfunction and senescence in immune myopathies","volume":"148","author":"Hou","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.ard.2025.08.031_bib0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-8955-3_9","article-title":"An application of computational drug repurposing based on transcriptomic signatures","volume":"1903","author":"Karatzas","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004558","article-title":"Experimental myositis: an optimised version of C-protein-induced myositis","volume":"11","author":"Giannini","year":"2025","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2025.08.031_bib0032","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/iep.12383","article-title":"Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice","volume":"102","author":"Micheletto","year":"2021","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ard.2025.08.031_bib0034","series-title":"U.S. Food and Drug Administration","article-title":"NINLARO (ixazomib) capsules, for oral use. Prescribing information","year":"2015"},{"key":"10.1016\/j.ard.2025.08.031_bib0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.08.004","article-title":"The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies","volume":"75","author":"Bhattarai","year":"2016","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.ard.2025.08.031_bib0036","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ard.2025.08.031_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","article-title":"Success in translational research: lessons from the development of bortezomib","volume":"5","author":"S\u00e1nchez-Serrano","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.ard.2025.08.031_bib0038","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.38180","article-title":"Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target","volume":"65","author":"Rayavarapu","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0039","doi-asserted-by":"crossref","first-page":"e9561","DOI":"10.15252\/emmm.201809561","article-title":"Inhibition of proteasome rescues a pathogenic variant of respiratory chain assembly factor COA7","volume":"11","author":"Mohanraj","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.ard.2025.08.031_bib0040","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910441","article-title":"Stop wasting protein-proteasome inhibition to target diseases linked to mitochondrial import","volume":"11","author":"Habich","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"9","key":"10.1016\/j.ard.2025.08.031_bib0041","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.031_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ard.2025.08.031_bib0043","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.08.031_bib0044","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.42988","article-title":"Unraveling the genetics of shared clinical and serological manifestations in patients with systemic inflammatory autoimmune diseases","volume":"77","author":"Bianchi","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.08.031_bib0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.ard.2025.08.031_bib0046","first-page":"A1","article-title":"Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: results from the openlabel phase 1B\/2 mission study","volume":"10","author":"Rovin","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.08.031_bib0047","article-title":"Zetomipzomib demonstrates favorable long-term safety and tolerability profile without signs of immunosuppression: results from the PRESIDIO study and its open-label extension study in patients with dermatomyositis and polymyositis [abstract]","volume":"75","author":"Aggarwal","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.031_bib0048","article-title":"Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.08.031_bib49","article-title":"Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis [abstract]","volume":"77","author":"Furie","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:18:03Z","timestamp":1779614283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0003496725043705"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.031","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}